Extended Data Figure 2: Mutants with enhanced human FcRn binding persist at higher serum concentrations than VRC01 in the human-FcRn(276)-transgenic mouse.
From: Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
The indicated VRC01-derived monoclonal antibodies (2 mg kg−1) were injected intravenously into 6–8-week-old human-FcRn(276)-transgenic mice (n = 4, male and female mice evenly distributed). Serum concentrations were assessed by indirect ELISA against RSC3 over time. The percentage of the monoclonal antibodies remaining in the serum is shown compared with the percentage on day 1 (set at 100%).
